Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Mahley RW, Weisgraber KH, Huang Y.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5644-51. Epub 2006 Mar 27. Review.

2.
3.

Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Mahley RW, Huang Y.

Neuron. 2012 Dec 6;76(5):871-85. doi: 10.1016/j.neuron.2012.11.020. Review.

4.

The pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based therapeutic approaches.

Iurescia S, Fioretti D, Mangialasche F, Rinaldi M.

J Alzheimers Dis. 2010;21(1):35-48. doi: 10.3233/JAD-2010-100009. Review.

PMID:
20182014
5.

Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease.

Mahley RW, Huang Y, Weisgraber KH.

Curr Alzheimer Res. 2007 Dec;4(5):537-40. Review.

PMID:
18220516
6.

Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology.

Baum L, Chen L, Ng HK, Pang CP.

Microsc Res Tech. 2000 Aug 15;50(4):278-81. Review.

PMID:
10936880
7.

Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.

Mahley RW.

J Mol Med (Berl). 2016 Jul;94(7):739-46. doi: 10.1007/s00109-016-1427-y. Epub 2016 Jun 9. Review.

8.

Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.

Huang Y.

Curr Opin Lipidol. 2010 Aug;21(4):337-45. doi: 10.1097/MOL.0b013e32833af368. Review.

PMID:
20531185
9.

Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease.

Mahley RW, Nathan BP, Pitas RE.

Ann N Y Acad Sci. 1996 Jan 17;777:139-45. Review.

PMID:
8624076
10.

Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism.

Mahley RW.

Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1305-15. doi: 10.1161/ATVBAHA.116.307023. Epub 2016 May 12. Review.

11.

Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease.

Huang Y, Weisgraber KH, Mucke L, Mahley RW.

J Mol Neurosci. 2004;23(3):189-204. Review.

PMID:
15181247
12.

Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies.

Huang Y.

Curr Opin Drug Discov Devel. 2006 Sep;9(5):627-41. Review.

PMID:
17002223
13.

The interaction of amyloid-beta with ApoE.

Carter DB.

Subcell Biochem. 2005;38:255-72. Review.

PMID:
15709483
14.

ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function.

Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ.

J Mol Neurosci. 2004;23(3):235-46. Review.

PMID:
15181252
15.

Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk.

Tai LM, Mehra S, Shete V, Estus S, Rebeck GW, Bu G, LaDu MJ.

Mol Neurodegener. 2014 Jan 4;9:2. doi: 10.1186/1750-1326-9-2. Review.

16.

Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.

Refolo LM, Fillit HM.

J Mol Neurosci. 2004;23(3):151-5. Review.

PMID:
15181243
17.

Impact of apolipoprotein E on Alzheimer's disease.

Hauser PS, Ryan RO.

Curr Alzheimer Res. 2013 Oct;10(8):809-17. Review.

18.

Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.

Huang Y.

Trends Mol Med. 2010 Jun;16(6):287-94. doi: 10.1016/j.molmed.2010.04.004. Epub 2010 May 27. Review.

PMID:
20537952
19.

Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease.

Roses AD, Saunders AM, Corder EH, Pericak-Vance MA, Han SH, Einstein G, Hulette C, Schmechel DE, Holsti M, Huang D, et al.

Arzneimittelforschung. 1995 Mar;45(3A):413-7. Review.

PMID:
7763336
20.

Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease.

Zlokovic BV.

JAMA Neurol. 2013 Apr;70(4):440-4. doi: 10.1001/jamaneurol.2013.2152. Review.

Supplemental Content

Support Center